Delivery of cancer therapies by synthetic and bio-inspired nanovectors.
Cancer therapy
Drug delivery
Nanomedicine
Nanoparticle
Targeting
Vectorization
Vesicle
Virus
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
24 03 2021
24 03 2021
Historique:
received:
04
12
2020
accepted:
05
03
2021
entrez:
25
3
2021
pubmed:
26
3
2021
medline:
1
12
2021
Statut:
epublish
Résumé
As a complement to the clinical development of new anticancer molecules, innovations in therapeutic vectorization aim at solving issues related to tumor specificity and associated toxicities. Nanomedicine is a rapidly evolving field that offers various solutions to increase clinical efficacy and safety. MAIN: Here are presented the recent advances for different types of nanovectors of chemical and biological nature, to identify the best suited for translational research projects. These nanovectors include different types of chemically engineered nanoparticles that now come in many different flavors of 'smart' drug delivery systems. Alternatives with enhanced biocompatibility and a better adaptability to new types of therapeutic molecules are the cell-derived extracellular vesicles and micro-organism-derived oncolytic viruses, virus-like particles and bacterial minicells. In the first part of the review, we describe their main physical, chemical and biological properties and their potential for personalized modifications. The second part focuses on presenting the recent literature on the use of the different families of nanovectors to deliver anticancer molecules for chemotherapy, radiotherapy, nucleic acid-based therapy, modulation of the tumor microenvironment and immunotherapy. This review will help the readers to better appreciate the complexity of available nanovectors and to identify the most fitting "type" for efficient and specific delivery of diverse anticancer therapies.
Sections du résumé
BACKGROUND
As a complement to the clinical development of new anticancer molecules, innovations in therapeutic vectorization aim at solving issues related to tumor specificity and associated toxicities. Nanomedicine is a rapidly evolving field that offers various solutions to increase clinical efficacy and safety. MAIN: Here are presented the recent advances for different types of nanovectors of chemical and biological nature, to identify the best suited for translational research projects. These nanovectors include different types of chemically engineered nanoparticles that now come in many different flavors of 'smart' drug delivery systems. Alternatives with enhanced biocompatibility and a better adaptability to new types of therapeutic molecules are the cell-derived extracellular vesicles and micro-organism-derived oncolytic viruses, virus-like particles and bacterial minicells. In the first part of the review, we describe their main physical, chemical and biological properties and their potential for personalized modifications. The second part focuses on presenting the recent literature on the use of the different families of nanovectors to deliver anticancer molecules for chemotherapy, radiotherapy, nucleic acid-based therapy, modulation of the tumor microenvironment and immunotherapy.
CONCLUSION
This review will help the readers to better appreciate the complexity of available nanovectors and to identify the most fitting "type" for efficient and specific delivery of diverse anticancer therapies.
Identifiants
pubmed: 33761944
doi: 10.1186/s12943-021-01346-2
pii: 10.1186/s12943-021-01346-2
pmc: PMC7987750
doi:
Substances chimiques
Drug Carriers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Références
Nano Lett. 2019 May 8;19(5):2993-3001
pubmed: 30964695
Acta Pharm. 2015 Jun;65(2):105-16
pubmed: 26011928
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
ACS Pharmacol Transl Sci. 2019 Dec 30;3(1):107-118
pubmed: 32259092
J Exp Clin Cancer Res. 2019 Sep 18;38(1):408
pubmed: 31533779
Front Immunol. 2020 Dec 21;11:601497
pubmed: 33408716
Mol Cancer Ther. 2016 Jan;15(1):199-208
pubmed: 26625896
Biomaterials. 2020 Apr;237:119827
pubmed: 32036302
Chem Sci. 2019 Jun 11;10(29):6932-6943
pubmed: 31588260
Biomacromolecules. 2019 Jan 14;20(1):469-477
pubmed: 30516960
Nano Res. 2016 May;9(5):1393-1408
pubmed: 27226823
Nano Lett. 2019 Jul 10;19(7):4362-4370
pubmed: 31199153
J Cell Physiol. 2020 Apr;235(4):3711-3720
pubmed: 31578716
Sci Adv. 2019 Aug 21;5(8):eaax0064
pubmed: 31457098
Biomater Sci. 2020 Nov 21;8(22):6113-6156
pubmed: 33025967
Adv Drug Deliv Rev. 2018 Sep;134:122-137
pubmed: 30267743
Gene Ther. 2017 Oct;24(10):649-660
pubmed: 28805798
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1594
pubmed: 31840427
Mol Pharm. 2019 Jun 3;16(6):2265-2277
pubmed: 31063396
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Pharm Res. 2016 Oct;33(10):2373-87
pubmed: 27299311
Adv Virol. 2012;2012:805629
pubmed: 22400027
Mol Pharm. 2019 May 6;16(5):1789-1798
pubmed: 30951627
J Immunother Cancer. 2017 Sep 19;5(1):71
pubmed: 28923104
Mol Ther Oncolytics. 2018 Sep 15;11:52-61
pubmed: 30364635
Nanoscale. 2017 Feb 9;9(6):2348-2357
pubmed: 28144662
Mol Pharm. 2013 Jan 7;10(1):69-76
pubmed: 23214968
Expert Opin Biol Ther. 2010 Sep;10(9):1331-41
pubmed: 20684738
Nanomedicine (Lond). 2020 Mar;15(7):661-676
pubmed: 32141806
Mol Pharm. 2013 Jan 7;10(1):33-42
pubmed: 22731633
Front Oncol. 2017 Jul 24;7:153
pubmed: 28791251
Biochemistry. 2016 May 10;55(18):2539-52
pubmed: 27074418
Biomed Pharmacother. 2017 Nov;95:1209-1218
pubmed: 28931213
Oncoimmunology. 2017 Dec 26;7(3):e1407897
pubmed: 29399408
PLoS One. 2018 Jul 25;13(7):e0201100
pubmed: 30044833
N Engl J Med. 2017 Sep 14;377(11):1065-1075
pubmed: 28902591
Viruses. 2016 Oct 22;8(10):
pubmed: 27782084
Nanomaterials (Basel). 2020 Feb 20;10(2):
pubmed: 32093140
Biomacromolecules. 2017 Dec 11;18(12):4141-4153
pubmed: 29144726
PLoS One. 2013 Nov 22;8(11):e79907
pubmed: 24278212
Front Immunol. 2018 Dec 11;9:2909
pubmed: 30619273
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):268-76
pubmed: 24837889
J Control Release. 2016 Feb 10;223:215-223
pubmed: 26732555
Lancet. 1975 Nov 8;2(7941):899-901
pubmed: 53375
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18571-18577
pubmed: 31375630
Mol Pharm. 2020 Dec 7;17(12):4629-4636
pubmed: 33186039
Invest New Drugs. 2013 Jun;31(3):696-706
pubmed: 22886613
Pharmaceutics. 2020 Mar 05;12(3):
pubmed: 32151052
J Clin Neurosci. 2015 Dec;22(12):1889-94
pubmed: 26279503
Annu Rev Med. 2018 Jan 29;69:289-299
pubmed: 29414253
Adv Drug Deliv Rev. 2017 Jan 15;109:84-101
pubmed: 26712711
Biomater Sci. 2020 Feb 7;8(3):763-775
pubmed: 31808476
Oncotarget. 2014 Aug 15;5(15):5893-907
pubmed: 25071017
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Nov-Dec;6(6):628-40
pubmed: 25196269
Cancer Gene Ther. 2020 Aug;27(7-8):515-527
pubmed: 31676843
J Control Release. 2018 Feb 10;271:60-73
pubmed: 29273320
Bioeng Transl Med. 2017 Jan 19;2(1):43-57
pubmed: 29313023
Nanoscale. 2018 Aug 30;10(34):16307-16313
pubmed: 30129956
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Nov;8(6):891-908
pubmed: 27038329
Br J Radiol. 2015 Oct;88(1054):20150185
pubmed: 26133075
Cancers (Basel). 2020 Jan 17;12(1):
pubmed: 31963415
Nat Rev Clin Oncol. 2020 Apr;17(4):251-266
pubmed: 32034288
Semin Cancer Biol. 2021 Feb;69:307-324
pubmed: 32259643
Adv Drug Deliv Rev. 2020;156:23-39
pubmed: 32450105
Theranostics. 2019 Oct 15;9(25):7826-7848
pubmed: 31695803
J Clin Oncol. 2016 Aug 1;34(22):2619-26
pubmed: 27298410
Cancer Treat Rev. 2016 Nov;50:129-141
pubmed: 27665540
Biomaterials. 2016 Jan;76:52-65
pubmed: 26519648
J Control Release. 2015 Feb 28;200:138-57
pubmed: 25545217
Int J Hyperthermia. 2015;31(5):498-506
pubmed: 25955015
Mol Ther. 2020 Oct 7;28(10):2286-2296
pubmed: 32682455
Cancer Gene Ther. 2020 May;27(5):301-310
pubmed: 31130731
Mol Ther Oncolytics. 2017 Mar 21;5:20-40
pubmed: 28480326
Eur J Pharmacol. 2018 Oct 15;837:117-126
pubmed: 30179611
Curr Gene Ther. 2005 Dec;5(6):595-605
pubmed: 16457649
Adv Mater. 2018 Nov;30(45):e1803397
pubmed: 30276880
Nanomedicine. 2016 Nov;12(8):2485-2498
pubmed: 27378204
Mol Ther Oncolytics. 2018 Jul 14;10:14-27
pubmed: 30073187
Clin Cancer Res. 2021 Feb 1;27(3):889-902
pubmed: 33257429
PLoS One. 2016 Apr 06;11(4):e0151832
pubmed: 27050167
Mol Cancer Res. 2017 Oct;15(10):1410-1420
pubmed: 28679779
J Control Release. 2017 Nov 28;266:17-26
pubmed: 28911805
Nat Rev Genet. 2020 Apr;21(4):255-272
pubmed: 32042148
Expert Opin Drug Deliv. 2018 Feb;15(2):185-196
pubmed: 28893110
J Virol. 2020 Jan 17;94(3):
pubmed: 31694938
Nat Commun. 2018 Apr 12;9(1):1410
pubmed: 29650952
J Pharmacol Exp Ther. 2019 Sep;370(3):715-724
pubmed: 30610006
Tumour Biol. 2015 Dec;36(12):9733-8
pubmed: 26156802
Cancer Cell. 2016 Jul 11;30(1):108-119
pubmed: 27374223
Angew Chem Int Ed Engl. 2009;48(50):9493-7
pubmed: 19921725
J Drug Target. 2016;24(3):179-91
pubmed: 26061298
Sci Rep. 2016 Jun 09;6:27559
pubmed: 27278751
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):2466-71
pubmed: 26884209
Adv Drug Deliv Rev. 2020;154-155:163-175
pubmed: 32745496
Drug Resist Updat. 2020 May;50:100682
pubmed: 32087558
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Mol Ther. 2020 May 6;28(5):1251-1262
pubmed: 32145203
J Am Chem Soc. 2009 Aug 12;131(31):11174-8
pubmed: 19603808
Int J Mol Sci. 2020 Jan 10;21(2):
pubmed: 31936832
Int Immunopharmacol. 2003 Mar;3(3):319-28
pubmed: 12639809
Int J Mol Sci. 2017 May 24;18(6):
pubmed: 28538671
Cancer Lett. 2010 May 1;291(1):67-75
pubmed: 19903581
Mol Pharm. 2018 Sep 4;15(9):4161-4172
pubmed: 30011369
Mol Ther Oncolytics. 2016 Mar 16;3:16004
pubmed: 27119118
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
Asian J Pharm Sci. 2020 Sep;15(5):576-590
pubmed: 33193861
J Virol Methods. 2008 Aug;151(2):172-180
pubmed: 18584885
Onco Targets Ther. 2020 Feb 13;13:1331-1341
pubmed: 32104000
Mol Ther. 2010 Apr;18(4):692-9
pubmed: 20087318
JCI Insight. 2018 Apr 5;3(7):
pubmed: 29618658
Nat Commun. 2018 Oct 31;9(1):4548
pubmed: 30382085
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Cancer Cell Int. 2018 Jul 13;18:101
pubmed: 30008618
Small. 2013 Jan 28;9(2):215-21
pubmed: 23047655
Mol Pharm. 2019 Mar 4;16(3):1184-1199
pubmed: 30698975
Oncotarget. 2016 Apr 26;7(17):23988-4004
pubmed: 26992211
J Control Release. 2020 Mar 10;319:63-76
pubmed: 31866504
J Thorac Oncol. 2020 May;15(5):827-842
pubmed: 31945495
Cancer Cell. 2007 May;11(5):431-45
pubmed: 17482133
Expert Opin Biol Ther. 2015 Jul;15(7):959-71
pubmed: 25959450
Front Immunol. 2019 Aug 21;10:1998
pubmed: 31497026
Curr Med Chem. 2018;25(34):4269-4303
pubmed: 29284391
Viruses. 2015 Jul 20;7(7):4075-92
pubmed: 26205404
Adv Healthc Mater. 2017 Jul;6(13):
pubmed: 28557249
Biomaterials. 2019 Aug;211:14-24
pubmed: 31078049
J Control Release. 2017 Nov 28;266:8-16
pubmed: 28916446
Recent Results Cancer Res. 2016;209:95-110
pubmed: 28101690
Eur J Pharm Sci. 2020 Mar 1;144:105213
pubmed: 31926941
ACS Nano. 2013 Feb 26;7(2):994-1005
pubmed: 23289892
An Acad Bras Cienc. 2018 May 14;90(1 Suppl 2):1233-1250
pubmed: 29768576
Annu Rev Virol. 2014 Nov;1(1):605-25
pubmed: 26958736
Science. 2020 Feb 7;367(6478):
pubmed: 32029601
Cancer Gene Ther. 2000 Jun;7(6):939-46
pubmed: 10880026
Int J Mol Sci. 2019 Mar 13;20(6):
pubmed: 30871158
Nat Nanotechnol. 2007 Apr;2(4):249-55
pubmed: 18654271
Adv Drug Deliv Rev. 2019 May;145:130-144
pubmed: 31004625
Cancer Cell. 2020 Mar 16;37(3):354-370.e7
pubmed: 32183951
Theranostics. 2018 Feb 12;8(6):1690-1705
pubmed: 29556350
Nat Biotechnol. 2017 Jun;35(6):543-550
pubmed: 28459452
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Nat Commun. 2018 Jan 2;9(1):6
pubmed: 29295974
Hum Gene Ther. 2012 May;23(5):484-91
pubmed: 22171635
Biomacromolecules. 2018 Jul 9;19(7):2377-2390
pubmed: 29864287
J Mater Chem B. 2018 Oct 7;6(37):5888-5895
pubmed: 30923616
J Immunother Cancer. 2019 Jan 25;7(1):19
pubmed: 30683154
Pharmacol Res. 2016 Sep;111:487-500
pubmed: 27394168
Theranostics. 2019 Jan 30;9(4):1015-1028
pubmed: 30867813
Ther Deliv. 2016 Sep;7(9):619-37
pubmed: 27582234
J Control Release. 2019 Jan 28;294:165-175
pubmed: 30557650
Nanomedicine. 2018 Jan;14(1):195-204
pubmed: 28982587
Clin Cancer Res. 2009 Sep 1;15(17):5396-403
pubmed: 19706820
Hum Gene Ther. 2018 Feb;29(2):151-159
pubmed: 29284308
Clin Cancer Res. 2005 Feb 15;11(4):1608-17
pubmed: 15746066
Mol Ther. 2012 Dec;20(12):2222-33
pubmed: 22948673
Adv Healthc Mater. 2019 Mar;8(6):e1801002
pubmed: 30450761
Biomed Pharmacother. 2017 Jun;90:586-597
pubmed: 28407579
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Nano Lett. 2019 Jul 10;19(7):4237-4249
pubmed: 30868883
Drug Discov Today. 2018 May;23(5):1159-1166
pubmed: 29660478
FASEB J. 2014 Feb;28(2):676-82
pubmed: 24186964
ACS Appl Mater Interfaces. 2020 Apr 8;12(14):16018-16030
pubmed: 32192326
Chem Rec. 2016 Aug;16(4):1833-51
pubmed: 27258402
J Control Release. 2015 Dec 28;220(Pt B):727-37
pubmed: 26390807
ACS Nano. 2016 Apr 26;10(4):4119-26
pubmed: 26982250
Drug Discov Today. 2020 Aug;25(8):1513-1520
pubmed: 32561300
Cancers (Basel). 2019 Oct 14;11(10):
pubmed: 31615145
Front Bioeng Biotechnol. 2019 Sep 20;7:228
pubmed: 31616663
Oncogene. 2018 Apr;37(16):2137-2149
pubmed: 29367765
Cell Cycle. 2007 Sep 1;6(17):2099-105
pubmed: 17786046
Radiat Oncol. 2015 Aug 07;10:165
pubmed: 26245485
EMBO Mol Med. 2019 Apr;11(4):
pubmed: 30808679
J Control Release. 2013 Sep 28;170(3):365-72
pubmed: 23770008
Nano Lett. 2017 Oct 11;17(10):6366-6375
pubmed: 28858519
Mol Ther. 2013 Feb;21(2):358-67
pubmed: 23229091
Virus Res. 2018 Sep 15;257:40-51
pubmed: 30125593
Nat Commun. 2020 Feb 20;11(1):972
pubmed: 32080195
Clin Epigenetics. 2019 May 16;11(1):81
pubmed: 31097014
Adv Drug Deliv Rev. 2020;154-155:37-63
pubmed: 32526452
MAbs. 2015;7(1):53-65
pubmed: 25523746
J Control Release. 2014 Sep 28;190:451-64
pubmed: 24794900
Drug Deliv. 2017 Nov;24(1):1909-1926
pubmed: 29191057
Viruses. 2020 Apr 27;12(5):
pubmed: 32349216
ACS Nano. 2017 Oct 24;11(10):9594-9613
pubmed: 28926225
Oncol Rep. 2017 Aug;38(2):611-624
pubmed: 28627697
BMC Cancer. 2010 Sep 13;10:486
pubmed: 20836854
Nat Rev Immunol. 2020 May;20(5):321-334
pubmed: 32005979
Drug Discov Today. 2018 Apr;23(4):900-911
pubmed: 29373841
Int J Mol Sci. 2019 May 10;20(9):
pubmed: 31083402
Cancer Res. 2018 Dec 15;78(24):6852-6865
pubmed: 30449733
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
Nat Rev Drug Discov. 2019 Jun;18(6):421-446
pubmed: 30846871
Nanomaterials (Basel). 2019 Apr 19;9(4):
pubmed: 31010180
Nat Rev Clin Oncol. 2020 Nov;17(11):657-674
pubmed: 32699309
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):E2811-E2818
pubmed: 29507241
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
Biomaterials. 2017 Mar;121:130-143
pubmed: 28088075
Biochem Biophys Res Commun. 2015 Oct 2;465(4):658-64
pubmed: 26241675
ACS Nano. 2011 Jul 26;5(7):5729-45
pubmed: 21615170
Bioconjug Chem. 2019 Feb 20;30(2):273-283
pubmed: 30525488
Cancer Res. 2001 Sep 15;61(18):6795-804
pubmed: 11559553
Biomaterials. 2017 Dec;147:155-168
pubmed: 28946131
Nat Commun. 2019 Jan 3;10(1):45
pubmed: 30604748
Oncolytic Virother. 2017 Nov 08;6:39-49
pubmed: 29184854
J Nanobiotechnology. 2019 Jul 18;17(1):85
pubmed: 31319859
Curr Mol Med. 2018;18(1):44-57
pubmed: 29663884
Gene Ther. 2020 Jun;27(6):266-280
pubmed: 32034293
Adv Healthc Mater. 2019 Jul;8(13):e1900132
pubmed: 31067008
Theranostics. 2019 Aug 12;9(20):5886-5898
pubmed: 31534526
Gene Ther. 2006 Oct;13(20):1457-70
pubmed: 16724095
Nat Biotechnol. 2009 Jul;27(7):643-51
pubmed: 19561595
Biomaterials. 2018 Apr;161:33-46
pubmed: 29421561
J Exp Clin Cancer Res. 2010 May 20;29:52
pubmed: 20487549
Bioconjug Chem. 2020 Jan 15;31(1):82-92
pubmed: 31809019
Drug Resist Updat. 2017 Mar;31:15-30
pubmed: 28867241
Drug Deliv. 2020 Dec;27(1):585-598
pubmed: 32264719
Curr Med Chem. 2019;26(33):6132-6148
pubmed: 30182846
Front Pharmacol. 2018 Aug 21;9:971
pubmed: 30186185
Curr Drug Metab. 2018;19(9):781-792
pubmed: 29749308
Biomed Pharmacother. 2020 May;125:109861
pubmed: 32070872
Cell. 2017 Sep 7;170(6):1109-1119.e10
pubmed: 28886381
J Control Release. 2015 Dec 10;219:76-94
pubmed: 26407670
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
J Control Release. 2020 Mar 10;319:1-14
pubmed: 31838205
Transl Cancer Res. 2012 Jun;1(2):4-14
pubmed: 22924158
J Control Release. 2020 Apr 10;320:180-200
pubmed: 31978444
Bioconjug Chem. 2019 Jun 19;30(6):1754-1762
pubmed: 31181889
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):113-128
pubmed: 26004498
PLoS One. 2015 Dec 11;10(12):e0144559
pubmed: 26659127
J Virol. 2011 Jun;85(11):5679-84
pubmed: 21450833
Nat Nanotechnol. 2018 Aug;13(8):746-754
pubmed: 29760523
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2481-2491
pubmed: 31219352
Bioeng Transl Med. 2019 Sep 05;4(3):e10143
pubmed: 31572799
J Control Release. 2016 Dec 10;243:357-369
pubmed: 27794494
J Bacteriol. 1973 Oct;116(1):226-9
pubmed: 4583211
Nat Commun. 2017 Oct 3;8(1):777
pubmed: 28974673
Clin Cancer Res. 2017 Oct 1;23(19):5696-5702
pubmed: 28679776
Biomaterials. 2019 Mar;197:368-379
pubmed: 30703742
Theranostics. 2016 Jun 07;6(9):1306-23
pubmed: 27375781
Drug Deliv. 2017 Nov;24(1):1419-1428
pubmed: 28937321
Int J Mol Sci. 2020 Feb 03;21(3):
pubmed: 32028729
Cells. 2020 Feb 24;9(2):
pubmed: 32102476
Biomacromolecules. 2014 Jun 9;15(6):1955-69
pubmed: 24798476
Int J Mol Sci. 2019 Jul 16;20(14):
pubmed: 31315232
J Control Release. 2017 Sep 28;262:247-258
pubmed: 28687495
Intervirology. 2012;55(4):276-86
pubmed: 21865658
Cancer Gene Ther. 2016 Jan;23(1):13-23
pubmed: 26564429
Immunol Lett. 2017 Oct;190:64-83
pubmed: 28760499
Int J Clin Exp Pathol. 2019 Jan 01;12(1):205-211
pubmed: 31933735
Adv Mater. 2017 Sep;29(35):
pubmed: 28722140
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
Nat Mater. 2020 May;19(5):566-575
pubmed: 31932672
Cancer Gene Ther. 2011 Apr;18(4):288-96
pubmed: 21183947
Cancer Gene Ther. 2013 Aug;20(8):478-85
pubmed: 23868101
Hum Gene Ther. 2018 Feb;29(2):160-179
pubmed: 29338444
Gene Ther. 2017 Jan;24(1):21-30
pubmed: 27779616
Theranostics. 2019 Jan 1;9(1):126-151
pubmed: 30662558
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Nano Converg. 2019 Jul 15;6(1):23
pubmed: 31304563
ACS Nano. 2019 Oct 22;13(10):11107-11121
pubmed: 31525954
Nano Lett. 2018 Jun 13;18(6):3571-3579
pubmed: 29722542
Nanoscale. 2019 Aug 7;11(29):13934-13946
pubmed: 31305839
Drug Des Devel Ther. 2020 Feb 26;14:823-832
pubmed: 32161442
Mol Ther. 2018 Apr 4;26(4):1008-1019
pubmed: 29478729
Small. 2019 Oct;15(40):e1902998
pubmed: 31441204
Biomaterials. 2019 May;201:33-41
pubmed: 30784770
Trends Pharmacol Sci. 2018 Jan;39(1):24-48
pubmed: 29224916
J Control Release. 2020 May 10;321:564-575
pubmed: 32112854
J Control Release. 2017 Oct 28;264:333-340
pubmed: 28890213
Adv Mater. 2020 Apr;32(17):e2000208
pubmed: 32147886
Small. 2017 Jul;13(25):
pubmed: 28544324
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Mol Pharm. 2016 Nov 7;13(11):3764-3772
pubmed: 27611245
Chem Biol Drug Des. 2015 Oct;86(4):606-13
pubmed: 25643992
Rev Med Virol. 2018 Nov;28(6):e2008
pubmed: 30209859
Adv Drug Deliv Rev. 2020;163-164:3-18
pubmed: 32229271
ACS Nano. 2018 Feb 27;12(2):912-931
pubmed: 29378114
J Radiat Res. 2018 Mar 1;59(suppl_1):i2-i10
pubmed: 29373709
Adv Mater. 2015 Nov 25;27(44):7043-50
pubmed: 26416431
Nano Lett. 2017 Jul 12;17(7):4019-4028
pubmed: 28650644
Acta Biochim Biophys Sin (Shanghai). 2018 Oct 1;50(10):1018-1027
pubmed: 30137199
Leukemia. 2017 Dec;31(12):2791-2798
pubmed: 28439108
Acta Neuropathol Commun. 2019 Apr 29;7(1):64
pubmed: 31036068
Theranostics. 2020 Feb 10;10(8):3474-3487
pubmed: 32206102
Oncotarget. 2017 Sep 26;8(70):114495-114505
pubmed: 29383097
ACS Nano. 2019 Feb 26;13(2):954-977
pubmed: 30681834
Nanomedicine. 2016 Feb;12(2):317-32
pubmed: 26706409
Sci Rep. 2017 Jul 13;7(1):5303
pubmed: 28706267
Methods Mol Biol. 2019;1895:1-9
pubmed: 30539525
BMC Cancer. 2019 Sep 14;19(1):921
pubmed: 31521130
Expert Opin Drug Deliv. 2015 Feb;12(2):223-38
pubmed: 25224685
Langmuir. 2012 Dec 18;28(50):17372-80
pubmed: 23163406
Nucleic Acids Res. 2011 Jan;39(Database issue):D576-82
pubmed: 20947564
Nucl Med Commun. 2010 May;31(5):405-10
pubmed: 20147862
Theranostics. 2020 Jan 12;10(4):1960-1980
pubmed: 32042347
Adv Mater. 2018 Jun;30(25):e1706098
pubmed: 29691900
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Front Bioeng Biotechnol. 2020 Sep 16;8:574007
pubmed: 33042975
Hum Gene Ther. 2019 Mar;30(3):352-364
pubmed: 30234393
Front Immunol. 2017 Nov 02;8:1442
pubmed: 29163515
Theranostics. 2020 Feb 19;10(8):3793-3815
pubmed: 32206123
Mayo Clin Proc. 2014 Jul;89(7):926-33
pubmed: 24835528
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33431631
Nano Lett. 2017 Feb 8;17(2):862-869
pubmed: 28027646
PLoS One. 2014 May 22;9(5):e98101
pubmed: 24851905
Curr Opin Biotechnol. 2011 Dec;22(6):909-16
pubmed: 21550793
Theranostics. 2016 Mar 25;6(6):795-807
pubmed: 27162550
Plasmid. 2012 Sep;68(2):69-85
pubmed: 22613563
Sci Rep. 2016 Nov 24;6:37891
pubmed: 27883070
Lancet Oncol. 2017 Oct;18(10):1386-1396
pubmed: 28870611